Quest Diagnostics INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
Quest Diagnostics announces a 10.2% increase in net revenues for Q2 2026, driven by significant volume growth in its Diagnostic Information Services segment.
NYSE
Quest Diagnostics announced a 9.2% increase in net revenues for Q1 2026, driven by robust growth in its Diagnostic Information Services (DIS) segment.
NYSE
Quest Diagnostics reports significant revenue and earnings growth in Q3 2025, driven by acquisitions and organic volume, despite increased operating costs and legal charges.
NYSE
Quest Diagnostics announced robust financial results for the second quarter and first half of 2025, with significant revenue and earnings growth primarily fueled by recent acquisitions and ongoing strategic initiatives.
NYSE
Quest Diagnostics' Q1 2025 net revenues increased by 12.1% year-over-year, primarily driven by recent acquisitions.
NYSE
Quest Diagnostics' Q3 2024 results show revenue growth driven by recent acquisitions and organic expansion, despite a slight decrease in operating income.
NYSE
Quest Diagnostics saw a modest revenue increase in the second quarter of 2024, driven by growth in its base business and recent acquisitions, while also managing restructuring and integration costs.
NYSE
Quest Diagnostics' first quarter results show a slight revenue increase but a decrease in net income, influenced by restructuring and acquisition activities.